CEA and CA 19-9 are Still Valuable Markers for the Prognosis of Colorectal and Gastric Cancer Patients

  • Sisik, Abdullah (Bingol State Hospital) ;
  • Kaya, Mustafa (Kangal State Hospital) ;
  • Bas, Gurhan (Umraniye Education and Research Hospital) ;
  • Basak, Fatih (Umraniye Education and Research Hospital) ;
  • Alimoglu, Orhan (Umraniye Education and Research Hospital)
  • Published : 2013.07.30


Background: The purpose of this study was to assess the predictive effect of preoperative CEA and CA 19-9 levels on the prognosis of colorectal and gastric cancer patients. Materials and Methods: CEA and CA 19-9 were evaluated preoperatively in patients undergoing surgery for colorectal cancer (n=116) and gastric cancer (n=49). Patients with CEA levels <5 ng/mL were classified as CEA Group 1, 5-30 ng/mL as CEA Group 2 and >30 ng/mL were classified as CEA Group 3. Similarly the patients with a CA 19-9 level <35 U/mL were classified as CA 19-9 Group 1, with 35-100 U/mL as Group 2 and with >100 U/mL as Group and 3. TNM stages and histologic grades were noted according to histopathological reports. Patients with a TNM grade 0 or 1 were classified as Group A, TNM grade 2 patients constituted Group B and TNM grade 3 and 4 patients constituted Group C. Demographic characteristics, tumor locations and blood types of the patients were all recorded and these data were compared with the preoperative CEA and CA19-9 values. Results: A significant correlation between CA 19-9 levels (>100 U/mL) and TNM stage (in advanced stages) was determined. We also determined a significant correlation between TNM stages and positive vlaues for both CEA and CA 19-9 in colorectal and gastric cancer patients. In comparison between CEA and CA 19-9 levels and age, gender, tumor location, ABO blood group, and tumor histologic grade, no significant correlation was found. Conclusions: Positive levels of both CEA and CA 19-9 can be considered to indicate an advanced stage in colorectal and gastric cancer patients.


Colorectal;gastric;tumour markers;CA 19-9;CEA;prognosis;disease stage


  1. Basbug M, Arikanoglu Z, Bulbuller N, et al (2011). Prognostic value of preoperative CEA and CA 19-9 levels in patients with colorectal cancer. Hepato-Gastroenterology, 58, 400-5.
  2. Carpelan-Holmstrom M, Louhimo J, Stenman UH, et al (2002). CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers. Anticancer Res, 22, 2311-5.
  3. Cooper HS (2004). Intestinal neoplasma. In Mills SE (eds): Sternberg's Diagnostic Surgical Pathology Lipincott Williams and Wilkins, 1543-58.
  4. Dalton P, Chandrasoma P (1999). Colorectal malignant neoplasm. In Chandrasoma P (eds): Gastrointestinal Pathology 1st Edition. Stamford Connecticut: Appleton and Lange, 339-26.
  5. Dong H, Tang J, Li LH, et al (2013).Serum carbohydrate antigen 19-9 as an indicator of liver metastasis in colorectal carcinoma cases. Asian Pac J Cancer Prev, 14, 1965-3.
  6. Duraker N, Celik AN (2001). The prognostic significance of preoperative serum CA 19-9 in patients with respectable gastric carcinoma: comparison with CEA. J Surg Oncol, 76, 266-5.
  7. Gonzales A, Vizoso F, Allende MT, et al (1996). Preoperative CEA and TAG-72 serum levels as prognostic indicators in resectable gastric carcinoma. Int J Biol Markers, 11, 165-6.
  8. Hamilton SR, Vogelstein B, Kudo S, et al (2000). Tumors of colon and rectum. In Hamilton SR, Altonen LA (eds): World health organisation classification of tumors. Pathology and genetics of tumors of the digestive system. France: IARC Pres, 103-40.
  9. Hammond EH (2002). Quality control and standardization for tumor markers. In Diamandis EP, Fritsche HA, Lilja H, Chan DW, Schwartz MK (eds): Tumor markers: Physiology, Pathobiology, Technology and Clinical Applications. AACC Press, 25-7.
  10. Harada H, Tsukada Y, Karasawa Y (1994). Evaluation of tumorassociated antigen (2H_6$ antigen) in detecting early stages of gastric cancer. Clin Chim Acta, 228, 101-12.
  11. Harpaz N, Saxena R. (2003). Gastrointestinal tract. Large Intestine. In Weidner N, Cote RJ, Suster S et al. (eds): Modern Surgial Pathology 2nd Edition. Saunders 749-103.
  12. Huh JW, Oh BR, Kim BR, Kim JY (2010). Preoperative carcinoembriyonic antigen level as an independent prognostic factor in potentially curative colon cancer. J Surg Oncol, 101, 396-400.
  13. Jass JR (2000). Tumours of the small and large intestines (Including the Anal region). In Fletcher CDM, Christopher D. (eds): Diagnostic Histopathology of Tumours 2nd Edition. Livingstone, 369-40.
  14. Mahmoud N, Rombeau J, Ross HM (2010). Colon and rectum. In Towsend CM, evers BM, beaucamps RD, mattox KL (eds): Sabiston Textbook of Surgery: the Biological Basis of Modern Surgical Practice 17th Edition. Saunders, 1401-83.
  15. McLeod HL, Murray GI (1999). Tumour markers of prognosis in colorectal cancer. Br J Cancer, 79, 191-203.
  16. Mihmanli M, Dilege E, Demir U, et al (2004). The use of tumor markers as predictors of prognosis in gastric cancer. Hepatogastroenterol, 51, 1544-7.
  17. Mittal A, Gupta SP, Jha DK, Sathian B, Poudel B (2013). Impact of various tumor markers in prognosis of gastric cancer. a hospital based study from Tertiary Care Hospital of Kathmandu Valley. Asian Pac J Cancer Prev, 14, 1965-3.
  18. Park YA, Lee KY, Kim NK, et al (2006). Prognostic effect of perioperative change of serum carcinoembriyonic antigen level: a useful tool for detection of systemic recurrence in rectal cancer. Ann Surg Oncol, 13, 645-50.
  19. Redston M (2004) Epithelial Neoplasms of the GI Tract (Large Intestine). In Odze RD, Goldblum JR (eds): Surgical Pathology of the GI Tract, Liver, Biliary Tract, and Pancreas 1st Edition. Saunders, 441-31.
  20. Reiter W, Steiber P, Reuter C, et al (2000). Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer. Anticancer Res, 20, 5195-8.
  21. Tocchi A, Costa G, Lepre L, et al (1998). The role of serum and gastric juice levels of carcinoembryonic antigen, CA 19.9 and CA 72.4 in patients with gastric cancer. J Cancer Res Clin Oncol, 124, 450-5.
  22. Ucar E, Semerci E, Ustun H, et al (2008). Prognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in gastric cancer. Adv Ther, 25, 1075-9.
  23. Uehara K, Miyamoto Y, Izuo M, et al (1985). Significance of CEA in gastric and colorectal cancer. Nippon Geka Gakkai Zasshi, 86, 435-7.
  24. Wanebo HJ, Rao B, Pinsky CM, et al (1978). Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N Engl Med, 299, 448-3.
  25. Yakabe T, Nakafusa Y, Sumi K, et al (2010). Clinical significance of CEA and CA 19-9 in postoperative follow-up of colorectal cancer. Ann Surg Oncol, 17, 2349-56.
  26. Yamashita K, Sakuramoto S, Kikuchi S, et al (2007). Surgical resection of stage IV gastric cancer and prognosis. Anticancer Res, 27, 4381-5.
  27. Yang XQ, Li Y, Chen C, et al (2001). Preoperative serum carbohydrate antigen 125 level is an independent negative prognostic marker for overall survival in colorectal cancer. Med Oncol, 28, 789-6.
  28. Ychou M, Duffour J, Kramar A, et al (2000). Clinical significance and prognostic value of CA 72-4 compared with CEA and CA 19-9 in patients with gastric cancer. Dis Markers, 16, 105-5.
  29. Zheng CX, Zhan WH, Zhao JZ, et al (2001). The prognostic value of preoperative serum levels of CEA, CA 19-9 and CA 72-4 in patients with colorectal cancer. World J Gastroentero, 7, 431-3.

Cited by

  1. Clinical Significance of Combined Detection of Serum Tumor Markers in Diagnosis of Patients with Ovarian Cancer vol.14, pp.11, 2013,
  2. DEPTOR Expression Negatively Correlates with mTORC1 Activity and Tumor Progression in Colorectal Cancer vol.15, pp.11, 2014,
  3. Preliminary Evaluation of Clinical Utility of CYFRA 21-1, CA 72-4, NSE, CA19-9 and CEA in Stomach Cancer vol.15, pp.12, 2014,
  4. Combined Detection of CEA, CA 19-9, CA 242 and CA 50 in the Diagnosis and Prognosis of Resectable Gastric Cancer vol.15, pp.15, 2014,
  5. Down-regulated MYH11 Expression Correlates with Poor Prognosis in Stage II and III Colorectal Cancer vol.15, pp.17, 2014,
  6. Increased Expression of P2RY2, CD248 and EphB1 in Gastric Cancers from Chilean Patients vol.15, pp.5, 2014,
  7. MicroRNAs as potential biomarkers for gastric cancer vol.20, pp.34, 2014,
  8. A Novel Electrochemical Microfluidic Chip Combined with Multiple Biomarkers for Early Diagnosis of Gastric Cancer vol.10, pp.1, 2015,
  9. Tumor Markers for Diagnosis, Monitoring of Recurrence and Prognosis in Patients with Upper Gastrointestinal Tract Cancer vol.15, pp.23, 2015,
  10. Comparative Study of Carcinoembryonic Antigen Tumor Marker in Stomach and Colon Cancer Patients in Khyber Pakhtunkhwa vol.16, pp.11, 2015,
  11. Factors Affecting Prognosis in Metastatic Colorectal Cancer Patients vol.16, pp.7, 2015,
  12. Differences and correlation of serum CEA, CA19-9 and CA72-4 in gastric cancer vol.4, pp.3, 2015,
  13. Preoperative Use of PET/CT in Patients With Colorectal and Gastric Cancer and Its Impact on Treatment Decision Making vol.101, pp.7-8, 2016,
  14. Diagnostic and prognostic value of CEA, CA19–9, AFP and CA125 for early gastric cancer vol.17, pp.1, 2017,
  15. Detection of metastatic cancer cells in mesentery of colorectal cancer patients vol.23, pp.34, 2017,